Journal article icon

Journal article

Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses

Abstract:

More than 190 vaccines are currently in development to prevent infection by the novel severe acute respiratory syndrome coronavirus 2. Animal studies suggest that while neutralizing antibodies against the viral spike protein may correlate with protection, additional antibody functions may also be important in preventing infection. Previously, we reported early immunogenicity and safety outcomes of a viral vector coronavirus vaccine, ChAdOx1 nCoV-19 (AZD1222), in a single-blinded phase 1/2 ran...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1038/s41591-020-01179-4

Authors


More by this author
Institution:
University of Oxford
Division:
MSD
Department:
Paediatrics
Role:
Author
More by this author
Division:
MSD
Department:
Paediatrics
Role:
Author
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
ORCID:
0000-0001-9827-9836
More by this author
Institution:
University of Oxford
Division:
MSD
Department:
NDM
Sub department:
Jenner Institute
Role:
Author
ORCID:
0000-0001-5330-0240
Expand authors...

Contributors

Division:
MSD
Role:
Contributor
Publisher:
Springer Nature Publisher's website
Journal:
Nature Medicine Journal website
Volume:
27
Pages:
279-288
Place of publication:
United States
Publication date:
2020-12-17
Acceptance date:
2020-11-16
DOI:
EISSN:
1546-170X
ISSN:
1078-8956
Pmid:
33335322
Language:
English
Keywords:
Pubs id:
1150312
Local pid:
pubs:1150312
Deposit date:
2021-01-01

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP